ADORA2A and Parkinson disease: In addition to the observed improved motor activity with istradefylline in animal models of PD, the selective A2AR antagonist significantly reduced ‘OFF’ symptoms in clinical trials, which was the basis for the FDA approval of istradefylline for the treatment of PD in conjunction with the conventional levodopa [42,63,64].